Background: Cancer patients are considered susceptible to coronavirus disease (COVID-19) due to an immunosuppressive state. This study determined the prevalence of cancer in COVID-19 patients, severe events, case fatality rate, history of anticancer therapy associated with severe events, and type of cancer in cancer patients with COVID-19 in the world. Methods: This study used a meta-analysis study approach, sourcing studies from various countries related to cancer and COVID-19. Inclusion and exclusion criteria were established to select studies. A PRISMA flowchart was presented to assess the selection process. Data from inclusion studies were analyzed using Review Manager 5.4. Results: The prevalence of cancer in COVID-19 patients was 4.63% (95% CI, 3.78-5.49%) worldwide. The lowest prevalence was the Asian study group with 2.36% (95% CI, 1.86-2.87%) and the highest prevalence was the European study group with 10.93% (95% CI, 6.62-15.24%). About 43.26% (95% CI, 34.71-51.80%) of cancer patients with COVID-19 experienced severe events of COVID-19. In total, 58.13% (95% CI, 42.79-73.48%) of cancer patients with COVID-19 who in the last month had a history of anticancer therapy experienced severe events. The prevalence of lung cancer in cancer patients with COVID-19 was 20.23% (95% CI, 7.67-32.78%). Forest plots are also presented related to the results of meta-analysis research. Conclusions: High prevalence of cancer among COVID-19 patients indicates the susceptibility of cancer patients to SARS-CoV-2 infection. Cancer in COVID-19 patients and use of anticancer therapy increase severe events of COVID-19.

Background: Cancer patients are considered susceptible to coronavirus disease (COVID-19) due to an immunosuppressive state. This study determined the prevalence of cancer as a comorbid in COVID-19 patients, severe events, case fatality rate, history of anticancer therapy associated with severe events, and type of cancer in cancer patients with COVID-19 in the world. Methods: This study used a meta-analysis study approach, sourcing studies from various countries related to cancer and COVID-19. Inclusion and exclusion criteria were established to select studies. A PRISMA flowchart was presented to assess the selection process. Data from inclusion studies were analyzed using Review Manager 5.4. Results: The prevalence of cancer as a comorbid in COVID-19 patients was 4.63% (95% CI, 3.78-5.49%) worldwide. The lowest prevalence was the Asian study group with 2.36% (95% CI, 1.86-2.87%) and the highest prevalence was the European study group with 10.93% (95% CI, 6.62-15.24%). About 43.26% (95% CI, 34.71-51.80%) of COVID-19 patients with cancer as comorbid experienced severe events of COVID-19. In total, 58.13% (95% CI, 42.79-73.48%) of COVID-19 patients with cancer as a comorbid who in the last month had a history of anticancer therapy experienced severe events. The prevalence of lung cancer in cancer patients with COVID-19 was 20.23% (95% CI, 7.67-32.78%). Forest plots are also presented related to the results of meta-analysis research. Conclusions: High prevalence of cancer as a comorbid among COVID-19 patients indicates the susceptibility of cancer patients to SARS-CoV-2 infection. Cancer as a comorbid in COVID-19 patients and use of anticancer therapy increase severe events of COVID-19.

Objective: To elicit quality of life of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin from clinical and humanistic outcome, to analysis characteristic factors to Hb, fatique and the quality of life (QOL) of CKD patients with routine hemodialysis, and to explore the change in QOL over one month for patients managed in the hospitals. Methods: A prospective study was conducted among adult CKD patients in Haji Adam Malik Hospital Medan. QOL was measured using kidney disease quality of life – short form (KDQOL–SFTM) questionnaire and FACIT fatigue scale questionnaire. CKD patients. Patients were asked to complete the KDQOL–SFTM questionnaire and FACIT fatigue scale questionnaire two times in one month range. Results: Average rate of haemoglobin was increased after one month anemia treatment using erythropoietin 8.68: 8.82. Average rate of FACIT was increased after one month anemia treatment using erythropoietin 43.98: 44.81. Average rate of KDQOL was increased after one month anemia treatment using erythropoietin 76.83: 77.94. Conclusion: Erythropoietin can improve QOL of CKD patients with routine hemodialysis.